Drugplain

Aczone 75 mg/g

dapsone · GEL · Almirall, LLC

No Recall History
Plain English

Aczone is a gel containing dapsone at 75 mg/g, taken topical. Manufactured by Almirall, LLC.

Key Facts

Brand Name
Aczone
Generic Name
dapsone
NDC Code (Product)
16110-526
Manufacturer
Almirall, LLC
Strength
75 mg/g
Dosage Form
GEL
Route
TOPICAL
Marketing Status
Application #
NDA207154
Drug Class
Sulfone [EPC]
Marketing Start
09/10/2019

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

off label use1,189 reports
drug ineffective1,128 reports
nausea479 reports
methaemoglobinaemia468 reports
fatigue462 reports
pyrexia457 reports
diarrhoea417 reports
rash387 reports
pneumonia382 reports
dyspnoea379 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE ACZONE ® (dapsone) Gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ACZONE ® Gel, 7.5%, is a sulfone indicated for the topical treatment of acne vulgaris in patients 9 years of age and older ( 1 ).

Dosage & Administration

2 DOSAGE AND ADMINISTRATION For topical use only. Not for oral, ophthalmic, or intravaginal use. After the skin is gently washed and patted dry, apply approximately a pea-sized amount of ACZONE Gel, 7.5%, in a thin layer to the entire face once daily. In addition, a thin layer may be applied to other affected areas once daily. Rub in ACZONE Gel, 7.5%, gently and completely. If there is no improvement after 12 weeks, treatment with ACZONE Gel, 7.5% should be reassessed. Apply once daily ( 2 ). Apply approximately a pea-sized amount of ACZONE Gel, 7.5%, in a thin layer to the entire face. A thin layer can also be applied to other affected areas ( 2 ). If there is no improvement after 12 weeks, treatment with ACZONE Gel, 7.5% should be reassessed ( 2 ). For topical use only. Not for oral, ophthalmic, or intravaginal use ( 2 ).

Contraindications

4 CONTRAINDICATIONS None. None ( 4 ).

Drug Interactions

7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted with ACZONE Gel, 7.5%. Trimethoprim/sulfamethoxazole (TMP/SMX) increases the systemic level of dapsone and its metabolites ( 7.1 ). Topical benzoyl peroxide used at the same time as ACZONE Gel, 7.5% may result in temporary local yellow or orange skin discoloration ( 7.2 ). 7.1 Trimethoprim-Sulfamethoxazole A drug-drug interaction study evaluated the effect of the use of dapsone gel, 5% in combination with double strength (160 mg/800 mg) trimethoprim-sulfamethoxazole (TMP/SMX). During co-administration, systemic levels of TMP and SMX were essentially unchanged, however, levels of dapsone and its metabolites increased in the presence of TMP/SMX. The systemic exposure from ACZONE Gel, 7.5% is expected to be about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX. 7.2 Topical Benzoyl Peroxide Topical application of dapsone gel followed by benzoyl peroxide in patients with acne vulgaris may result in a temporary local yellow or orange discoloration of the skin and facial hair. 7.3 Drug Interactions with Oral Dapsone Certain concomitant medications (such as rifampin, anticonvulsants, St.

Adverse Reactions

6 ADVERSE REACTIONS Most common (incidence ≥ 0.9%) adverse reactions are application site dryness and pruritus ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Almirall at 1-866-665-2782 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 2161 subjects were treated with ACZONE Gel, 7.5%, for 12 weeks in 2 controlled clinical trials. The population ranged in age from 12 to 63 years, was 56% female, and 58% Caucasian. Adverse drug reactions that were reported in at least 0.9% of subjects treated with ACZONE Gel, 7.5% appear in Table 1 below. Table 1. Adverse Reactions Occurring in at Least 0.9% of Subjects with Acne Vulgaris in 12-week Controlled Clinical Trials ACZONE Gel, 7.5% (N=2161) Vehicle (N=2175) Application Site Dryness 24 (1.1%) 21 (1.0%) Application Site Pruritus 20 (0.9%) 11 (0.5%) 6.2 Experience with Oral Use of Dapsone Although not observed in the clinical trials

Frequently Asked Questions

What is Aczone used for?

Aczone contains dapsone. It is a gel taken topical. Consult your doctor for specific uses.

Is Aczone a controlled substance?

Aczone is not classified as a controlled substance by the DEA.

What is the generic name for Aczone?

The generic name for Aczone is dapsone. There are 12 other brand versions of dapsone.

What is the NDC code for Aczone 75 mg/g?

The NDC (National Drug Code) for Aczone 75 mg/g is 16110-526, listed by Almirall, LLC.

Product NDC

16110-526

Package NDC

16110-526-60

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)